Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-05-28
Schrödinger, Inc.
Schrödinger sells physics-based molecular discovery software and hosted workflows to pharma and other research customers, while also monetizing partnered and proprietary drug programs built on the same platform.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow control matters more than pipeline heroics
The upside case is a cleaner scientific software model with partner-funded therapeutic optionality. If hosted workflows and AI modules deepen adoption inside major pharma accounts, revenue quality can improve enough for a meaningful re-rating without betting on a single drug win.

Analysis

Thesis
If Schrödinger converts its installed pharma footprint into a deeper hosted workflow layer, it can grow from a respected modeling vendor into a higher-quality discovery operating system with partner-funded drug upside; the real bet is on more throughput, trust, and budget share per large account, not on self-funding a big pipeline.
Last Economy Alignment
Cheaper cognition and more compute should expand demand for validated molecular design workflows, and Schrödinger owns a real control point in scientific process software. It benefits meaningfully, but it is not a hard standard and still faces agent-layer and pricing pressure risks.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.6x (from 5 most recent analyses)
Reasoning
The upside is a quality upgrade in what investors think they are owning. If hosted delivery, workflow embedment, and new AI-assisted discovery surfaces turn Schrödinger into a broader operating layer inside major pharma accounts, revenue becomes more durable, expansion gets easier, and the market can pay a better multiple than it does for a transition-distorted hybrid today. I still cap the outcome below true platform leaders because pricing and workflow control remain only partly proven.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is strategic proof, not solvency. Schrödinger needs to show that hosted workflows and new AI surfaces increase account-level value capture faster than they compress pricing, while partner-funded therapeutics must stay an upside option rather than a cash drain. If customers treat the platform as useful plumbing instead of a control layer, revenue quality improves but valuation upside stays limited.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.60
They own a real checkpoint in drug-discovery workflow software, so cheaper AI and more compute can push more work through their system. The risk is that generic agents or cheaper tools sit on top of the workflow and turn them into a back-end engine instead of the place where value is captured.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.88
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case